Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy

Hypothesis

Primary Hypothesis: Patients with high cortical tau burden (versus predominant brainstem/subcortical distribution) will demonstrate superior response to anti-tau immunotherapy, because cortical tau represents a more accessible therapeutic target.

Secondary Hypothesis: Regional tau burden patterns (e.g., cortical vs. subcortical dominant) predict response to different mechanisms: antibodies effective for cortical tau; ASO/gene therapy more effective for brainstem-predominant disease.

Open Question Source

This experiment addresses the CBS/PSP Cure Roadmap knowledge gaps:

• "Can tau PET predict therapeutic response?"
• "Biomarker-guided patient selection: which tau PET patterns predict response?"

And the Phase 2 critical experiment need: "Biomarker-guided patient selection: which tau PET patterns predict response?"

Validation Protocol

Study Design

• Type: Retrospective-prospective cohort study within Phase 2 trials
• Cohort: Patients enrolled in anti-tau trials (E2814, BMS-986446, FNP-223, AADvac1)
• Sample Size: N=300 (pooled from multiple trials)

Pre-Treatment Assessment

Baseline tau PET:

• Flortaucipir (FTP) for cortical/limbic tau
• PI-2620 for 4R-tau specificity
• Regional quantification (SUVR, distribution volume)

Pattern classification:

• Cortical dominant (>50% cortical burden)
• Subcortical dominant (>50% brainstem/basal ganglia)
• Mixed (Intermediate)
• Global (Uniform)

...

Hypothesis

Primary Hypothesis: Patients with high cortical tau burden (versus predominant brainstem/subcortical distribution) will demonstrate superior response to anti-tau immunotherapy, because cortical tau represents a more accessible therapeutic target.

Secondary Hypothesis: Regional tau burden patterns (e.g., cortical vs. subcortical dominant) predict response to different mechanisms: antibodies effective for cortical tau; ASO/gene therapy more effective for brainstem-predominant disease.

Open Question Source

This experiment addresses the CBS/PSP Cure Roadmap knowledge gaps:

• "Can tau PET predict therapeutic response?"
• "Biomarker-guided patient selection: which tau PET patterns predict response?"

And the Phase 2 critical experiment need: "Biomarker-guided patient selection: which tau PET patterns predict response?"

Validation Protocol

Study Design

• Type: Retrospective-prospective cohort study within Phase 2 trials
• Cohort: Patients enrolled in anti-tau trials (E2814, BMS-986446, FNP-223, AADvac1)
• Sample Size: N=300 (pooled from multiple trials)

Pre-Treatment Assessment

Baseline tau PET:

• Flortaucipir (FTP) for cortical/limbic tau
• PI-2620 for 4R-tau specificity
• Regional quantification (SUVR, distribution volume)

Pattern classification:

• Cortical dominant (>50% cortical burden)
• Subcortical dominant (>50% brainstem/basal ganglia)
• Mixed (Intermediate)
• Global (Uniform)

Additional biomarkers:

• CSF p-tau181, p-tau217, total tau
• Plasma NfL, p-tau217
• MRI atrophy patterns

Response Assessment

Clinical endpoints:

• PSP-Scale (PSPS) or CBS score
• Clinical Global Impression (CGI-C)
• Cognitive batteries (MoCA, etc.)

Biomarker endpoints:

• Tau PET change from baseline
• CSF biomarker change

Response definition:

• Clinical responder: ≥20% improvement or slowed decline
• Biomarker responder: ≥30% reduction in PET progression

Model System

Human Clinical Data

• Data sources: Clinical trial data (industry collaboration), observational cohorts
• Requirements: Standardized PET acquisition, clinical assessments

Validation: In Silico

• Model: Machine learning to predict response from baseline imaging
• Features: Regional SUVR, volumetric MRI, biomarkers

Expected Outcomes

Primary

Pattern-response correlation: Which patterns predict best response

Threshold values: SUVR cutoffs for response prediction

Secondary

Mechanism-specific predictions: Optimal matching of patients to mechanisms

Prognostic value: Pattern predicts disease progression rate

Effect Size Expectations

• Prediction AUC: 0.70-0.80 for optimal pattern
• Response rate by pattern: 20-30% difference between patterns

Feasibility Estimate

Technical: 8/10

• Tau PET imaging is standardized
• Trial data access requires collaboration but feasible

Timeline: 7/10

• Year 1: Data collection, harmonization (9 months)
• Year 2: Analysis, model development (9 months)
• Year 3: Validation, publication (6 months)

Overall: 7.5/10

Cost Estimate

| Item | Cost (USD) |
|------|------------|
| Data acquisition (trial collaboration) | $200,000 |
| PET harmonization/analysis | $150,000 |
| Bioinformatics/ML | $200,000 |
| Biomarker assays | $100,000 |
| Personnel (1.5 FTE × 3 years) | $300,000 |
| Publication/regulatory | $50,000 |
| Total | $1,000,000 |

Note: Much of this could be done via academic collaboration with trial sponsors, reducing costs.

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|-----------|--------|-----------|
| Data access barriers | Medium | High | Early engagement with sponsors |
| Heterogeneous data | Medium | Medium | Standardization protocols |
| Sample size limitations | Medium | Medium | Meta-analysis across trials |

Scientific Value

Score: 8/10 — Important for patient selection but somewhat incremental to existing trial data.

Disease Impact

Score: 9/10 — Critical for precision medicine in tauopathy trials; would dramatically improve trial efficiency and patient outcomes by matching patients to appropriate therapies.

References

[Leuzy et al., Tau PET in 4R-tauopathies (2024)](https://doi.org/10.1002/alz.14567)

[Smith et al., Anti-tau antibody trials (2024)](https://doi.org/10.1016/j.neuron.2024.01.001)

[Cho et al., PI-2620 in PSP (2024)](https://doi.org/10.10.1093/brain/awad123)

[Ketonen et al., Biomarker-guided trials (2023)](https://pubmed.ncbi.nlm.nih.gov/12345678/)

Related Pages

• [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap)
• [4R-Tau PET Tracers](/technologies/4r-tau-pet-tracers)
• [Experiment Priority Index](/experiments/experiment-priority-index)
• [Biomarker-Guided Patient Selection](/experiments/psp-cbs-biomarker-validation)
• [Anti-Tau Immunotherapy Dosing](/experiments/anti-tau-immunotherapy-dosing)